{
    "clinical_study": {
        "@rank": "48648", 
        "arm_group": {
            "arm_group_label": "ibrutinib", 
            "arm_group_type": "Experimental", 
            "description": "ibrutinib capsules: 560 mg once daily"
        }, 
        "brief_summary": {
            "textblock": "Phase 2, open-label, non-randomized, monotherapy study to evaluate the safety and efficacy\n      of ibrutinib in subject with relapsed/refractory Marginal Zone Lymphoma (MZL)."
        }, 
        "brief_title": "Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Marginal Zone Lymphoma", 
            "B-cell Lymphoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, B-Cell", 
                "Lymphoma, B-Cell, Marginal Zone"
            ]
        }, 
        "detailed_description": {
            "textblock": "Ibrutinib is a first-in-class, potent, orally administered covalent inhibitor of Bruton's\n      tyrosine kinase (BTK).  Inhibition of BTK blocks downstream B-cell receptor (BCR) signaling\n      pathways and thus prevents B-cell proliferation. In vitro, ibrutinib inhibits purified BTK\n      and selected members of the kinase family with 10-fold specificity compared with non-BTK\n      kinases.  Phase 1 and 2 studies of ibrutinib in B-cell malignancies demonstrate modest\n      toxicity and significant single agent activity in a variety of B-cell malignancies,\n      including NHL."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion criteria:\n\n          -  Histologically documented marginal zone lymphoma (including splenic, nodal, and\n             extranodal sub-types)\n\n          -  Previously received one or more lines of therapy including at least one CD20-directed\n             regimen (either as monotherapy or as chemoimmunotherapy) with documented failure to\n             achieve at least PR or documented PD after, the most recent systemic treatment\n             regimen\n\n          -  Men and women \u226518 years of age\n\n          -  ECOG performance status of \u22642\n\n          -  \u22651 measurable disease site on CT scan (>1.5 cm in longest dimension). Lesions in\n             anatomical locations (such as extremities or soft tissue lesions) that are not well\n             visualized by CT may be measured by MRI instead.\n\n          -  Life expectancy of >3 months, in the opinion of the investigator\n\n        Key Exclusion criteria:\n\n          -  Medically apparent CNS lymphoma or leptomeningeal disease\n\n          -  History of other malignancies except adequately treated non melanoma skin cancer,\n             curatively treated in-situ cancer, or other solid tumors curatively treated with no\n             evidence of disease for \u22652 years\n\n          -  History of allogeneic stem-cell (or other organ) transplantation\n\n          -  Any chemotherapy, anticancer antibodies, or other systemic anticancer therapy within\n             21 days of the first dose of study drug\n\n          -  Any external beam radiation therapy within 6 weeks prior to the first dose of the\n             study drug\n\n          -  Concurrent use of warfarin or other vitamin K antagonists\n\n          -  Concurrent use of a strong CYP3A inhibitor.  Subjects who have received a strong\n             CYP3A inhibitor prior to entering the study must have discontinued therapy for at\n             least 5 half lives of the prohibited medication.\n\n          -  Recent infection requiring IV anti-infective treatment that was completed \u226414 days\n             before the first dose of study drug\n\n          -  Unresolved toxicities from prior anti-cancer therapy, defined as having not resolved\n             to CTCAE Grade 0 or 1, or to the levels dictated in the eligibility criteria with the\n             exception of alopecia\n\n          -  Inadequate organ function as defined on laboratory tests"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01980628", 
            "org_study_id": "PCYC-1121-CA"
        }, 
        "intervention": {
            "arm_group_label": "ibrutinib", 
            "intervention_name": "ibrutinib", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "keyword": [
            "MZL", 
            "NHL", 
            "SMZL", 
            "NMZL", 
            "MALT"
        ], 
        "lastchanged_date": "May 28, 2014", 
        "location": [
            {
                "contact": {
                    "email": "ccorpus@coh.org", 
                    "last_name": "Cheryl Corpus", 
                    "phone": "626-256-4673", 
                    "phone_ext": "31311"
                }, 
                "facility": {
                    "address": {
                        "city": "Duarte", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91010"
                    }, 
                    "name": "City of Hope"
                }, 
                "investigator": {
                    "last_name": "Robert Chen, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "bgutierrez@mednet.ucla.edu", 
                    "last_name": "Baudelio Gutierrez", 
                    "phone": "310-582-4046"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90095"
                    }, 
                    "name": "University of California Los Angeles"
                }, 
                "investigator": {
                    "last_name": "Sven deVos, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "j7perez@ucsd.edu", 
                    "last_name": "Jenny Perales", 
                    "phone": "858-822-6937"
                }, 
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92093"
                    }, 
                    "name": "University of California San Diego Moores Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Januario Castro, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jbar-nur@flcancer.com", 
                    "last_name": "Jennifer Bar-Nur", 
                    "phone": "561-472-1696"
                }, 
                "facility": {
                    "address": {
                        "city": "West Palm Beach", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33401"
                    }, 
                    "name": "Florida Cancer Specialists"
                }, 
                "investigator": {
                    "last_name": "Robert Jacobson, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jose.zavala@northwestern.edu", 
                    "last_name": "Jose Zavala"
                }, 
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }, 
                    "name": "Northwestern University"
                }, 
                "investigator": {
                    "last_name": "Shuo Ma, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "kthomas9@hfhs.org", 
                    "last_name": "Kathern Thomason", 
                    "phone": "313-916-7827"
                }, 
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48202"
                    }, 
                    "name": "Henry Ford Health System"
                }, 
                "investigator": {
                    "last_name": "Nalini Janakiraman, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Lymphoma Service", 
                    "phone": "646-497-9137"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }, 
                    "name": "Memorial Sloan-Kettering Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Ariela Noy, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ckats@researchcra.com", 
                    "last_name": "Colleen Kats", 
                    "phone": "855-737-2873", 
                    "phone_ext": "121"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10021"
                    }, 
                    "name": "Clinical Research Alliance"
                }, 
                "investigator": {
                    "last_name": "Morton Coleman, MD, FACP", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "pem9019@med.cornell.edu", 
                    "last_name": "Peter Martin, MD", 
                    "phone": "646-962-2068"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10021"
                    }, 
                    "name": "Weill Cornell Medical College"
                }, 
                "investigator": {
                    "last_name": "Peter Martin, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ccapper@hmc.psu.edu", 
                    "last_name": "Christine Capper", 
                    "phone": "717-531-0003", 
                    "phone_ext": "285453"
                }, 
                "facility": {
                    "address": {
                        "city": "Hershey", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "17033"
                    }, 
                    "name": "Penn State Milton S. Hershey Medical Center"
                }, 
                "investigator": {
                    "last_name": "Christopher Ehmann, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "lhedin@fhcrc.org", 
                    "last_name": "Lacey Hedin", 
                    "phone": "206-667-2731"
                }, 
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98109"
                    }, 
                    "name": "Seattle Cancer Care Alliance"
                }, 
                "investigator": {
                    "last_name": "Stephen Smith, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ghent", 
                        "country": "Belgium", 
                        "state": "Oost-Vlaanderen", 
                        "zip": "9000"
                    }, 
                    "name": "Universitair Ziekenhuis Gent"
                }, 
                "investigator": {
                    "last_name": "Fritz Offner", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "laure.ditullio-gaillon@chb.unicancer.fr", 
                    "last_name": "Laure Gaillon", 
                    "phone": "+33232082220"
                }, 
                "facility": {
                    "address": {
                        "city": "Rouen Cedex 1", 
                        "country": "France", 
                        "state": "Haute-Normandie", 
                        "zip": "76038"
                    }, 
                    "name": "Centre Henri-Becquerel"
                }, 
                "investigator": {
                    "last_name": "Herve Tilly", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "feriel.bouabbas@hmn.aphp.fr", 
                    "last_name": "Feriel Bouabbas", 
                    "phone": "+33149814182"
                }, 
                "facility": {
                    "address": {
                        "city": "Cr\u00e9teil", 
                        "country": "France", 
                        "state": "Ile de France", 
                        "zip": "94010"
                    }, 
                    "name": "Centre Hospitalier Universitaire Henri Mondor"
                }, 
                "investigator": {
                    "last_name": "Corinne Haioun", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris Cedex 10", 
                        "country": "France", 
                        "state": "Ile de France", 
                        "zip": "75475"
                    }, 
                    "name": "H\u00f4pital Saint Louis"
                }, 
                "investigator": {
                    "last_name": "Catherine Thieblemont", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Limoges Cedex", 
                        "country": "France", 
                        "state": "Limousin, Lorraine", 
                        "zip": "87042"
                    }, 
                    "name": "CHRU de Limoges - H\u00f4pital Dupuytren"
                }, 
                "investigator": {
                    "last_name": "Dominique Bordessoule", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "carole.delecroix@chru-lille.fr", 
                    "last_name": "Carole Delecroix", 
                    "phone": "+33320444284"
                }, 
                "facility": {
                    "address": {
                        "city": "Lille Cedex", 
                        "country": "France", 
                        "state": "Nord pas de Calais", 
                        "zip": "59037"
                    }, 
                    "name": "Centre Hospitalier R\u00e9gional Universitaire de Lille - H\u00f4pital Claude Huriez"
                }, 
                "investigator": {
                    "last_name": "Franck Morschhauser", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "helene.renoul@chd-vendee.fr", 
                    "last_name": "H\u00e9l\u00e8ne Renoul", 
                    "phone": "+33251446467"
                }, 
                "facility": {
                    "address": {
                        "city": "La Roche-sur-Yon Cedex 9", 
                        "country": "France", 
                        "state": "Pays de la Loire"
                    }, 
                    "name": "CHD Vend\u00e9e, Site de La Roche-sur-Yon, Les Oudairies"
                }, 
                "investigator": {
                    "last_name": "Herv\u00e9 Maisonneuve", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "alexis.morice@chu-nantes.fr", 
                    "last_name": "Alexis Morice", 
                    "phone": "+33240084030"
                }, 
                "facility": {
                    "address": {
                        "city": "Nantes cedex 1", 
                        "country": "France", 
                        "state": "Pays de la Loire", 
                        "zip": "44093"
                    }, 
                    "name": "Centre Hospitalier Universitaire Nantes, Hotel Dieu"
                }, 
                "investigator": {
                    "last_name": "Steven LeGouill", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "severine.seemann@chu-lyon.fr", 
                    "last_name": "Severine Seemann", 
                    "phone": "+33478864337"
                }, 
                "facility": {
                    "address": {
                        "city": "Pierre B\u00e9nite Cedex", 
                        "country": "France", 
                        "state": "Rhone- Alpes", 
                        "zip": "69495"
                    }, 
                    "name": "Centre Hospitalier Lyon Sud"
                }, 
                "investigator": {
                    "last_name": "Gilles Salles", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "anna.bernard@chu-rennes.fr", 
                    "last_name": "Anna Bernard", 
                    "phone": "+33299284321"
                }, 
                "facility": {
                    "address": {
                        "city": "Rennes cedex 9", 
                        "country": "France"
                    }, 
                    "name": "Centre Hospitalier Universitaire de Rennes, H\u00f4pital Pontchaillou"
                }, 
                "investigator": {
                    "last_name": "Sophie De Guibert, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Belgium", 
                "France"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multicenter, Open-Label, Phase 2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects With Relapsed/Refractory Marginal Zone Lymphoma", 
        "other_outcome": {
            "measure": "To evaluate prognostic and predictive biomarkers relative to treatment outcomes", 
            "safety_issue": "No", 
            "time_frame": "36 weeks after last patient enrolled"
        }, 
        "overall_contact": {
            "email": "medinfo@pcyc.com", 
            "last_name": "Susie Tanamly", 
            "phone": "855-427-8846"
        }, 
        "overall_contact_backup": {
            "email": "medinfo@pcyc.com", 
            "last_name": "Deepali Suri", 
            "phone": "855-427-8846"
        }, 
        "overall_official": {
            "affiliation": "Pharmacyclics", 
            "last_name": "Darrin Beaupre, MD, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board", 
                "Belgium: Federal Agency for Medicines and Health Products, FAMHP", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "France: National Agency for the Safety of Medicine and Health Products"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "To evaluate efficacy using the Overall Response Rate (ORR) as assessed by an Independent Review Committee (IRC) in subjects with MZL", 
            "safety_issue": "No", 
            "time_frame": "36 weeks after last patient enrolled"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01980628"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "To evaluate efficacy parameter such as duration of response (DOR) to ibrutinib in subjects with MZL", 
                "safety_issue": "No", 
                "time_frame": "36 weeks after last patient enrolled"
            }, 
            {
                "measure": "Frequency, severity, and relatedness of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "36 weeks after last patient enrolled"
            }, 
            {
                "measure": "To determine the plasma pharmacokinetics of ibrutinib and the metabolite, PCI-45227", 
                "safety_issue": "No", 
                "time_frame": "36 weeks after last patient enrolled"
            }, 
            {
                "measure": "To evaluate efficacy parameter such as progression-free survival (PFS) to ibrutinib in subjects with MZL", 
                "safety_issue": "No", 
                "time_frame": "36 weeks after last patient enrolled"
            }, 
            {
                "measure": "To evaluate efficacy parameter such as overall survival (OS) to ibrutinib in subjects with MZL", 
                "safety_issue": "No", 
                "time_frame": "36 weeks after last patient enrolled"
            }
        ], 
        "source": "Pharmacyclics", 
        "sponsors": {
            "collaborator": {
                "agency": "Janssen Research & Development, LLC", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Pharmacyclics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}